Skip to main content

Table 1 Audience responses to questions before the talks and after the discussion period

From: Psychosocial controversies in breast cancer

Before/after discussion Yes No Unsure
Is patient representation on trial steering committees helpful?    
   Before 53 16 32
   After 44 38 18
Should patients be involved in clinical trial design?    
   Before 38 39 23
   After 32 56 11
Do patient advocacy groups help speed up introduction of new drugs in the clinic?    
   Before 63 24 13
   After 90 8 2
Are patient advocacy groups responsible for distorting cancer budget in favour of breast over other tumours?    
   Before 79 11 10
   After 66 30 5
Should formal QoL play a major role in the management of MBC patients?    
   Before 73 14 14
   After 90 8 2
Are patient self-reports in QoL questionnaires more accurate than clinicians' records of side effects?    
   Before 50 25 25
   After 80 8 13
When making decisions about local surgical therapy women prefer ...a    
   Before 10 (Dr to choose) 83 (joint decision) 7 (patient choice)
   After 5 (Dr to choose) 81 (joint decision) 14 (patient choice)
Should breast cancer patients be encouraged to try complementary therapy?    
   Before 23 48 29
   After 31 38 31
Do nonprescription drugs help the symptoms and side effects?    
   Before 39 20 41
   After 38 23 39
  1. aFor this question, the options were 'Dr to choose', 'joint decision' and 'patient choice'. MBC, metastatic breast cancer; QoL, quality of life.